Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
He, JX; Su, CX; Liang, WH; Xu, SD; Wu, L; Fu, XN; Zhang, XD; Ge, D; Chen, Q; Mao, WM; Xu, L; Chen, C; Hu, B; Shao, GG; Hu, J; Zhao, J; Liu, XQ; Liu, ZD; Wang, Z; Xiao, ZM; Gong, TQ; Lin, W; Li, XY; Ye, F; Liu, Y; Ma, HT; Huang, YC; Zhou, JY; Wang, ZL; Fu, JK; Ding, LM; Mao, L; Zhou, CC
He, JX (corresponding author), Guangzhou Med Univ, Dept Thorac Surg & Oncol, Affiliated Hosp 1, Guangzhou 510120, Peoples R China.; Zhou, CC (corresponding author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China.; Zhou, CC (corresponding author), Tongji Univ, Sch Med, Thorac Canc Inst, Shanghai 200433, Peoples R China.
LANCET RESPIRATORY MEDICINE, 2021; 9 (9): 1021
